Bevacizumab After Chemoradiotherapy For Locally Advanced Lung Adenocarcinoma

Inclusion Criteria: * Pathologic confirmation of lung adenocarcinoma * Patients have measurable or evaluable lesions based on the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. * Eastern Cooperative Oncology Group (ECOG) performance status 0-1. * Unresectable, refusing surgery or after R2 surgery ,confirmed by PET-CT or chest and abdominal CT, craniocerebral MRI, and ECT. * After radiotherapy and chemotherapy, the tumor is in partial remission, complete remission or stable. * 1-2 months after chemoradiotherapy ends. * Organ and bone marrow functions were normal within the first 30 days of enrollment, including: • AST, ALT≤ 2.5\*ULN or ≤5\*ULN (with liver metastasis); • TBil ≤ 1.5 ULN • neutrophils absolute value ≥500 cells/mm3 • creatinine clearance ≥45 mL/min ;• platelets≥50,000 cells/mm3. * CB6 within normal limits * Patients and their family signed the informed consents Exclusion Criteria: * Lung squamous carcinoma. * The tumor has completely approached, encircled, or invaded the intravascular space of the great vessels (e.g., the pulmonary artery or the superior vena cava). * The tumor was associated with a cavity over 2cm in diameter. * Bleeding tendency or coagulation disorder. * Patients with hemoptysis (1/2 teaspoon blood/day) within 1 month. * Full-dose anticoagulation therapy was used within the past 1 month. * Severe vascular disease occurred within 6 months. * Gastrointestinal fistula, perforation or abdominal abscess occurred within 6 months. * Hypertensive crisis, hypertensive encephalopathy, symptomatic heart failure (New York class II or above), active cerebrovascular disease or cardiovascular disease occurred within 6 months. * Uncontrolled hypertension (systolic \> 150mmHg and/or diastolic \> 100mmHg). * Major surgery within 28 days or minor surgery or needle biopsy within 48 hours. * Urine protein 3-4+, or 24h urine protein quantitative \>1g. * Degree 3 esophagitis after chemoradiotherapy has not recovered. * Elderly patients (age 75 years). * The investigator does not consider the participant to be eligible for this study.